EpCAM⁺ Extracellular Vesicle PD-L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response.

Authors

Byeonggeol Mun, Jinyoung Kim, Chang Gon Kim, Seokhyeong Go, Mina Han, Yujin Ouck, Soojin Jang, Seong Uk Son, Gamin Kim, Wonrak Son, Eunjung Kim, Min Hee Hong, Ja Hyun Yeo, Eun-Kyung Lim, Hye Ryun Kim, Seungjoo Haam

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e76389. Jul 03, 2026. Epub Jul 03, 2026.

Abstract

Programmed death-ligand 1 (PD-L1) blockade improves outcomes in patients with various malignancies; however, biomarkers for monitoring treatment responses are lacking. This study presents a surface-enhanced Raman scattering (SERS)-based platform for the ultrasensitive detection of PD-L1 on circulating epithelial cell adhesion molecule-positive (EpCAM⁺) extracellular vesicles (EVs). The platform is validated using interferon-gamma-treated epithelial tumor cell line-derived EVs. The platform is further applied to paired pre- and post-treatment plasma samples from patients with non-small-cell lung cancer (n = 140) and head and neck squamous cell carcinoma (n = 73) receiving anti-PD-(L)1 immunotherapy. Dynamic changes in PD-L1 expression on EV are shown to correlate with clinical outcomes. A post-treatment decrease in PD-L1 expression on EpCAM⁺ EVs (EpCAM⁺ EV PD-L1) is associated with improved 5-year progression-free and overall survival. These results establish EpCAM⁺ EV PD-L1 as a dynamic, non-invasive biomarker for monitoring immunotherapy responses and demonstrate the utility of SERS-based profiling in predicting long-term responses to immune checkpoint blockade.

PMID:
42397059
Bibliographic data and abstract were imported from PubMed on 03 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.